
ARAY · NASDAQ
Accuray Incorporated
$0.12 -0.02 (-14.29%)
Company overview
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used to treat primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy System, including the Radixact System, which enables integrated radiation treatment planning, delivery, and data management, allowing clinicians to treat approximately 50 patients per day with ultra-precise care.
- Sector
- Healthcare
- Industry
- Medical - Devices
- Exchange
- NASDAQ
- Market cap
- $14.3M
- Employees
- 987
- Headquarters
- Madison, WI
- Website
- accuray.com
- CEO
- Stephen R. LaNeve
- Listed
- February 8, 2007
- P/E
- -0.30
- Dividend yield
- 0.00%
Company financials
- Revenue
- $429M
- Gross profit
- $115M
- Operating income
- -$15.1M
- EBITDA
- -$6.5M
- Net income
- -$46.1M
- EPS
- -$0.37
- Total assets
- $448M
- Total debt
- $182M
- Gross margin
- 26.81%
- Net margin
- -10.76%
- Earnings yield
- -335.91%
Showing FY 2026
News